Elsevier

Biochemical Pharmacology

Volume 38, Issue 9, 1 May 1989, Pages 1389-1393
Biochemical Pharmacology

Glucuronidation of 3'-azido-3'-deoxythymidine: Human and rat enzyme specificity

https://doi.org/10.1016/0006-2952(89)90177-9Get rights and content

Abstract

Since preclinical studies indicated that 3'-azido-3'-deoxythymidine (AZT, zidovudine, Retrovir®, BW A509U), a potent anti-HIV agent, is not metabolized extensively in rats, rabbits, mice, guinea pigs, cats, or dogs [1,2], the extensive biotransformation of AZT observed in humans was not expected. On average, approximately 75% of an oral AZT dose is recovered in human urine as a single metabolite while only 14–18% of the dose is recovered unchanged [1, 3]. Ultraviolet, infrared, nuclear magnetic resonance, and mass spectra and enzymatic degradation characterized the isolated major metabolite as a 5'-O-glucuronide (3'-azido-3'-deoxy-5'-ß-D-glucopyranuronosylthymidine, GAZT), a very unique nucleoside metabolite [1]. These observations suggest that UDP-glucuronosyltransferase (UDPGT), EC2.4.1.17, mediates the in vivo biotransformation of AZT to GAZT. Since glucuronidation is one of the major conjugation reactions involved in the metabolic conversion of xenobiotics to more polar, water-soluble metabolites, it is an important detoxification pathway in humans. Therefore, it is important to understand the enzymatic basis for the discrepancy between metabolism of AZT in laboratory mammals and humans. This is especially relevant in light of the use of laboratory mammals to predict the metabolism of novel pharmaceutical agents in humans. The study presented herein confirms that liver UDPGT does catalyze the glucuronidation of AZT and that the higher substrate efficiency of AZT with human enzyme compared to rodent enzyme may account for metabolic differences observed in vivo.

References (14)

There are more references available in the full text version of this article.

Cited by (49)

  • Stability-indicating micellar liquid chromatography method for three novel derivatives of zidovudine in aqueous and simulated gastric and intestinal fluids matrices

    2011, Journal of Chromatography A
    Citation Excerpt :

    Despite worldwide attempts underway to develop chemotherapeutic agents that are effective against HIV, 3′-azido-2′,3′-dideoxythymidine, or zidovudine (AZT) (Fig. 1), the first drug approved for the treatment of AIDS patients [12], is still one of the most potent active agents against HIV, and is used as a primary option in AIDS treatment in combination with other HIV inhibitors. Nevertheless, utility of AZT is limited by its toxic effect on bone marrow [13], hepatic abnormalities [14], limited brain uptake [15], short half-life time in plasma [16], high susceptibility to catabolism [17], general myopathy [18], lipoatrophy [19] and the rapid progress of resistance by HIV-1 [20]. For these reasons, numerous chemical strategies have been developed by medicinal scientists to design analogues or prodrugs of AZT to increase its therapeutic efficacy [21].

  • Liver Slices as a Model in Drug Metabolism

    1997, Advances in Pharmacology
View all citing articles on Scopus
View full text